Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
This trial will find the best dose of mifepristone when given together with nab-paclitaxel
(Abraxane) based on the side effects of the two drugs in patients with advanced breast
cancer.
Patients will be randomized to receive nab-paclitaxel with or without mifepristone during the
first treatment cycle. After the first cycle, all patients will receive nab-paclitaxel with
mifepristone until their disease worsens or they experience an unacceptable side effect.
This study will test up to 4 doses of mifepristone in combination with nab-paclitaxel. The
study will first test the lowest dose in a small group of patients and if they do not have
bad side effects, higher doses will be tested.